Efficacy of Continuous Glucose Monitoring in People Living with Diabetes and End Stage Kidney Disease on Dialysis: a Systematic Review

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Oct 25

PMID 39455937

Authors

Yimeng Zhang

Pushpa Singh

Kavitha Ganapathy

Vijayan Suresh

Muhammad Ali Karamat

Jyoti Baharani

Srikanth Bellary

Affiliations

Soon will be listed here.

Abstract

Background: Patients with diabetes on dialysis experience wide variations in glucose levels and an increased risk of hypoglycaemia. Due to the inaccuracies of HbA1c in dialysis patients, JBDS-IP and KDIGO recommend the use of continuous glucose monitoring (CGM). We conducted a systematic review to examine the current evidence for CGM use and its impact on clinical outcomes in patients with diabetes on dialysis.

Methods: A search of MEDLINE(R) ALL, Ovid Emcare, Journals@Ovid Full Text and Embase databases were conducted. Clinical or observational trials in adults with Type 1(T1D) or Type 2 (T2D) diabetes on dialysis and CGM intervention reporting on glycaemic outcomes were included.

Results: Of the 936 citations identified, 49 duplicates were removed. 887 citations were screened by title and abstract. 9 full texts were reviewed and a further 7 excluded due to duplications or failure to meet to selection criteria. Data was extracted for 2 studies, both prospective before-and-after interventional studies with no control group. Joubert et al. (2015) showed results for 15 participants with T1D. Mean CGM glucose level decreased from 8.37mmol/L at baseline to 7.7mmol/L at the end of the CGM period (p < 0.05) while HbA1c decreased from 6.9 to 6.5% (p < 0.05) during the same period. Mean CGM was lower on dialysis days (7.68mmol/L vs. 7.8mmol/L, p < 0.05). Képénékian et al. (2014) reported on data from 29 T2D patients. Following a 3 month CGM-adapted insulin regimen, HbA1c decreased from 8.4% at baseline to 7.6% (p < 0.01) by the end of study. Mean CGM values decreased from 9.9mmol/L to 8.9mmol/L (p = 0.05) and the frequency of glucose values > 10mmol/L decreased from 41 to 30% (p < 0.05), without a significant increase in hypoglycaemia frequency. Both studies were deemed to be of 'good' quality.

Conclusion: Evidence demonstrating the benefits of CGM in patients with diabetes receiving dialysis is lacking. There is a need for well-designed randomised controlled trials to ascertain the benefits of this technology in this patient group.

Trail Registration: PROSPERO registration number: CRD42023371635, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=371635 .

Citing Articles

Research Progress on the Application of CGM in Patients with Diabetes and Hemodialysis.

Huang P, He J, Ren L, Yang R, Feng D, Li L Int J Med Sci. 2024; 21(15):3083-3090.

PMID: 39628691 PMC: 11610330. DOI: 10.7150/ijms.102727.

References

Deshmukh H, Wilmot E, Gregory R, Barnes D, Narendran P, Saunders S . Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care. 2020; 43(9):2153-2160. PMC: 7440900. DOI: 10.2337/dc20-0738. View

De Marchi S, Cecchin E, Camurri C, Quaia P, Raimondi A, Donadon W . Origin of glycosylated hemoglobin A1 in chronic renal failure. Int J Artif Organs. 1983; 6(2):77-82. View

Qayyum A, Chowdhury T, Oei E, Fan S . Use of Continuous Glucose Monitoring in Patients with Diabetes Mellitus on Peritoneal Dialysis: Correlation with Glycated Hemoglobin and Detection of High Incidence of Unaware Hypoglycemia. Blood Purif. 2016; 41(1-3):18-24. DOI: 10.1159/000439242. View

Rahhal M, Gharaibeh N, Rahimi L, Ismail-Beigi F . Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. J Clin Endocrinol Metab. 2019; 104(11):4949-4966. DOI: 10.1210/jc.2019-00286. View

Jin Y, Su X, Yin G, Xu X, Lou J, Chen J . Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy. J Diabetes Complications. 2015; 29(3):395-9. DOI: 10.1016/j.jdiacomp.2014.12.015. View

Li P, Culleton B, Ariza A, Do J, Johnson D, Sanabria M . Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013; 24(11):1889-900. PMC: 3810077. DOI: 10.1681/ASN.2012100987. View

Christy A, Manjrekar P, Babu R, Hegde A, Rukmini M . Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. Iran Biomed J. 2014; 18(2):88-93. PMC: 3933917. DOI: 10.6091/ibj.1257.2014. View

Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y . Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015; 107(3):348-54. DOI: 10.1016/j.diabres.2015.01.026. View

Luyckx V, Tonelli M, Stanifer J . The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6):414-422D. PMC: 5996218. DOI: 10.2471/BLT.17.206441. View

10.

Sudha M, Salam H, Viveka S, Udupa A . Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017; 8(1):64-68. PMC: 5320826. DOI: 10.4103/0976-9668.198348. View

11.

Kazempour-Ardebili S, Lecamwasam V, Dassanyake T, Frankel A, Tam F, Dornhorst A . Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009; 32(7):1137-42. PMC: 2699727. DOI: 10.2337/dc08-1688. View

12.

Bomholt T, Kofod D, Norgaard K, Rossing P, Feldt-Rasmussen B, Hornum M . Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?. Nephron. 2022; 147(2):91-96. DOI: 10.1159/000525676. View

13.

. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S):S1-S115. DOI: 10.1016/j.kint.2020.06.019. View

14.

Joseph K, Avari P, Goldet G, Edwards C, McCarthy S, Reed J . The impact of diabetes specialist nurses' in-reach service on people with diabetes on haemodialysis: A pilot study 'education to protect tomorrow'. Diabet Med. 2024; 41(7):e15306. DOI: 10.1111/dme.15306. View

15.

Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M . Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med. 1998; 37(10):826-30. DOI: 10.2169/internalmedicine.37.826. View

16.

Yoo D, Park J, Oh H, Kim S, Lee M, Shin D . Good glycemic control is associated with better survival in diabetic patients on peritoneal dialysis: a prospective observational study. PLoS One. 2012; 7(1):e30072. PMC: 3264549. DOI: 10.1371/journal.pone.0030072. View

17.

Ling J, Ng J, Chan J, Chow E . Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease. Front Endocrinol (Lausanne). 2022; 13:869899. PMC: 9074296. DOI: 10.3389/fendo.2022.869899. View

18.

Kepenekian L, Smagala A, Meyer L, Imhoff O, Alenabi F, Serb L . Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol. 2014; 82(4):240-6. DOI: 10.5414/CN108280. View

19.

Bally L, Gubler P, Thabit H, Hartnell S, Ruan Y, Wilinska M . Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int. 2019; 96(3):593-596. DOI: 10.1016/j.kint.2019.03.006. View

20.

. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225):709-733. PMC: 7049905. DOI: 10.1016/S0140-6736(20)30045-3. View